Product Name :
TT-OAD2 free base
Description:
TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 free base has the potential for diabetes treatment.
CAS:
1246826-07-2
Molecular Weight:
856.83
Formula:
C50H47Cl2N3O6
Chemical Name:
(2S)-2-{[(3S,8S)-3-{4-[(3,4-dichlorophenyl)methoxy]phenyl}-7-[(1S)-1-phenylpropyl]-2H,3H,6H,7H,8H,9H-[1,4]dioxino[2,3-g]isoquinolin-8-yl]formamido}-3-[4-(2,3-dimethylpyridin-4-yl)phenyl]propanoic acid
Smiles :
CC[C@@H](C1C=CC=CC=1)N1CC2=CC3O[C@H](COC=3C=C2C[C@H]1C(=O)N[C@@H](CC1C=CC(=CC=1)C1=CC=NC(C)=C1C)C(O)=O)C1C=CC(=CC=1)OCC1=CC(Cl)=C(Cl)C=C1
InChiKey:
DEDPYBWOUXWMOX-ZTAAISNPSA-N
InChi :
InChI=1S/C50H47Cl2N3O6/c1-4-44(35-8-6-5-7-9-35)55-27-38-26-47-46(60-29-48(61-47)36-15-17-39(18-16-36)59-28-33-12-19-41(51)42(52)22-33)25-37(38)24-45(55)49(56)54-43(50(57)58)23-32-10-13-34(14-11-32)40-20-21-53-31(3)30(40)2/h5-22,25-26,43-45,48H,4,23-24,27-29H2,1-3H3,(H,54,56)(H,57,58)/t43-,44-,45-,48+/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 free base has the potential for diabetes treatment.|Product information|CAS Number: 1246826-07-2|Molecular Weight: 856.83|Formula: C50H47Cl2N3O6|Chemical Name: (2S)-2-{[(3S,8S)-3-{4-[(3,4-dichlorophenyl)methoxy]phenyl}-7-[(1S)-1-phenylpropyl]-2H,3H,6H,7H,8H,9H-[1,4]dioxino[2,3-g]isoquinolin-8-yl]formamido}-3-[4-(2,3-dimethylpyridin-4-yl)phenyl]propanoic acid|Smiles: CC[C@@H](C1C=CC=CC=1)N1CC2=CC3O[C@H](COC=3C=C2C[C@H]1C(=O)N[C@@H](CC1C=CC(=CC=1)C1=CC=NC(C)=C1C)C(O)=O)C1C=CC(=CC=1)OCC1=CC(Cl)=C(Cl)C=C1|InChiKey: DEDPYBWOUXWMOX-ZTAAISNPSA-N|InChi: InChI=1S/C50H47Cl2N3O6/c1-4-44(35-8-6-5-7-9-35)55-27-38-26-47-46(60-29-48(61-47)36-15-17-39(18-16-36)59-28-33-12-19-41(51)42(52)22-33)25-37(38)24-45(55)49(56)54-43(50(57)58)23-32-10-13-34(14-11-32)40-20-21-53-31(3)30(40)2/h5-22,25-26,43-45,48H,4,23-24,27-29H2,1-3H3,(H,54,56)(H,57,58)/t43-,44-,45-,48+/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Acacetin} MedChemExpress|{Acacetin} Autophagy|{Acacetin} Purity & Documentation|{Acacetin} Data Sheet|{Acacetin} manufacturer|{Acacetin} Cancer} |Shelf Life: ≥12 months if stored properly.{{Saracatinib} MedChemExpress|{Saracatinib} Autophagy|{Saracatinib} Biological Activity|{Saracatinib} In Vitro|{Saracatinib} supplier|{Saracatinib} Epigenetic Reader Domain} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:24455443 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-arrestin responses in a concentration-dependent manner in HEK293A cells.|In Vivo:|TT-OAD2 (3 mg/kg; intravenous injection; male human GLP-1 receptor knock-in and knockout mice) treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice.|Products are for research use only. Not for human use.|